Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China
— Junshi grants AstraZeneca exclusive promotion rights of toripalimab in mainland China for the urothelial carcinoma indications and for all indications in non-core areas —…